Activin Receptors, Type II
"Activin Receptors, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the two types of ACTIVIN RECEPTORS. They are membrane protein kinases belonging to the family of PROTEIN-SERINE-THREONINE KINASES. The major type II activin receptors are ActR-IIA and ActR-IIB.
| Descriptor ID |
D030301
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.062.750 D12.776.543.750.750.400.820.500.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Activin Receptors, Type II".
Below are MeSH descriptors whose meaning is more specific than "Activin Receptors, Type II".
This graph shows the total number of publications written about "Activin Receptors, Type II" by people in this website by year, and whether "Activin Receptors, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 2 | 2 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Activin Receptors, Type II" by people in Profiles.
-
Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology. Proc Natl Acad Sci U S A. 2024 Nov 19; 121(47):e2413108121.
-
Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes? Clin Adv Hematol Oncol. 2024 Oct; 22(8):367-369.
-
Safety and efficacy of luspatercept for the treatment of anemia in?patients with myelofibrosis. Blood Adv. 2024 09 10; 8(17):4511-4522.
-
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Sep; 11(9):e646-e658.
-
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 2023 11; 37(11):2314-2318.
-
Germline genetic mutations in pediatric cerebrovascular anomalies: a multidisciplinary approach to screening, testing, and management. J Neurosurg Pediatr. 2023 03 01; 31(3):212-220.
-
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with?ring sideroblasts. Blood. 2022 11 17; 140(20):2170-2174.
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 05; 36(5):1432-1435.
-
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2022 01 27; 139(4):624-629.
-
Endometrial receptivity and implantation require uterine BMP signaling through an ACVR2A-SMAD1/SMAD5 axis. Nat Commun. 2021 06 07; 12(1):3386.